AI and Rare Diseases ── 2026-11-15
New papers on rare diseases (other than neurological and cancer) and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 8 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Platforms(0) · Inborn errors of metabolism(0) · Genetic syndromes(0) · Rare blood disorders(1) · Immune and connective tissue(0) · Heart and lung(0) · Kidney, liver and gut(1) · Skin and bone(0)
Rare-disease diagnosis and drug discovery platforms and AI
No new qualifying paper for this issue.
Inborn errors of metabolism: treatment, trials and AI
No new qualifying paper for this issue.
Genetic syndromes and paediatric rare diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare blood disorders: treatment, trials and AI
- Abstract
Thalassemia is one of the most heterogeneous diseases, with more than a thousand mutation types recorded worldwide. Molecular diagnosis of thalassemia by conventional PCR-based DNA analysis is time- and resource-consuming owing to the phenotype variability, disease complexity, and molecular diagnostic test limitations. Thalassemia diagnosis relies heavily on complex interactions among hematological biomarkers, making it challenging to distinguish causal relationships from mere statistical correlations. To address this limitation, this study proposes a causal machine learning framework that integrates causal discovery and counterfactual inference to identify biomarker-driven treatment effects for thalassemia diagnosis. The proposed approach models clinical variables using a Directed Acyclic Graph (DAG) to capture underlying causal dependencies and enables robust estimation of treatment effects while accounting for confounding factors. To address the primary objective from complementary causal perspectives, the framework combines adjusted regression for confounding control, inverse probability weighting for propensity-based estimation, Random Forest-based analysis for nonlinear feature importance and heterogeneous treatment effects, and bootstrap resampling for uncertainty quantification. The adjusted linear regression model yielded a conservative causal effect estimate of 0.3008, while propensity-based methods demonstrated stronger effects, with IPW producing an estimate of 1.0604. The bootstrap approach confirmed the stability of these findings with a 95% confidence interval of [0.8806, 1.2161], indicating statistically significant treatment influence. Furthermore, heterogeneous effect analysis using CATE revealed substantial variability across individuals, with estimates ranging between 0.0848 and 2.5200, highlighting the importance of personalized assessment. Stratified analysis across age groups showed distinct differences, with the highest effect observed in adolescents (1.3484) and lower effects in children (0.8856), emphasizing demographic-specific variations. The results demonstrate that key biomarkers, particularly hemoglobin-related features, exert significant causal influence on thalassemia diagnosis.
Journal IF-equivalent: 3.4 (OpenAlex 2-year mean citedness, value as of 2026-11-13, retrieved 2026-11-15; not the official Clarivate IF)Reference: ElRashidy N, Elsabagh MA, Hassan E, El Fouhil AF, Alhussainy MY, Aljohani SAS, et al. Machine learning for biomarker-driven thalassemia diagnosis: a framework for causal effect estimation. Front Med (Lausanne). 2026 Oct 29;13:1926776. doi:10.3389/fmed.2026.1926776. PMID: 43021880.Checked: Abstract only
See all 1 Rare blood disorders papers →
Autoinflammatory, immunodeficiency and rare connective-tissue diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare cardiovascular and respiratory diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare kidney, liver and gastrointestinal diseases: treatment, trials and AI
- Abstract
Additional file 1: Table 1. Training set patient characteristics. Figure 1. Distribution of DSC for the in-house (left) and TotalSegmentator (right) models on the test set of 60 cases (2 consecutive scans of 30 patients).
Journal IF: unknown (could not be matched)Reference: [No authors listed]. Additional file 1 of Assessment of autosomal dominant polycystic kidney disease severity using deep learning–based kidney volumetry in CT. Figshare. [Epub ahead of print]. doi:10.6084/m9.figshare.35000147.Checked: Abstract only
See all 1 Kidney, liver and gut papers →
Rare skin and bone diseases: treatment, trials and AI
No new qualifying paper for this issue.